The Cancer Letter

Inside information on cancer research and drug development

In Brief

Candel Therapeutics partners with UPenn to study viral immunotherapy and CAR T-cell therapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Candel Therapeutics Inc., a clinical-stage biopharmaceutical company developing viral immunotherapies, formed a collaboration with the University of Pennsylvania to study the impact of novel viral immunotherapies based on Candel’s proprietary enLIGHTEN Discovery Platform to strengthen the effects of Penn’s CAR-T cell therapies in solid tumor models.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Table of Contents

Login

Looking for IP Login?